Wide Ranks

LQDA

Liquidia Corporation

11.62

Top Statistics
Market Cap 983 M Forward PE -9.19 Revenue Growth -23.50 %
Current Ratio 6.08 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -8.06 Enterprise / Revenue 52.03 Price To Sales Trailing12 Months 66.24
Profitability
Profit Margins 0.00 % Operating Margins -743.29 %
Balance Sheet
Total Cash 133 M Total Cash Per Share 1.73 Total Debt 88 M
Total Debt To Equity 141.69 Current Ratio 6.08 Book Value Per Share 0.6890
All Measures
Short Ratio 1226.00 % Message Board Id finmb_22761611 Fax 919 328 4402
Shares Short Prior Month 11 M Return On Equity -1.82 City Morrisville
Uuid 4e9d716d-8a04-3fbc-8a5a-0151bfd0dd75 Previous Close 11.42 First Trade Date Epoch Utc 1 B
Book Value 0.6890 Beta 0.2050 Total Debt 88 M
Volume 485461 Price To Book 16.86 Fifty Two Week Low 6.82
Total Cash Per Share 1.73 Total Revenue 14 M Shares Short Previous Month Date 1 B
Target Median Price 27.00 Audit Risk 9 Max Age 86400
Recommendation Mean 1.50 Sand P52 Week Change 0.3133 Operating Margins -743.29 %
Target Mean Price 25.44 Net Income To Common -112110000 Short Percent Of Float 0.1888
Implied Shares Outstanding 84 M Trailing Peg Ratio None Last Fiscal Year End 1 B
Average Daily Volume10 Day 852150 Average Volume10days 852150 Total Cash 133 M
Next Fiscal Year End 1 B Revenue Per Share 0.2100 Held Percent Insiders 0.1949
Trailing PE 0.0000 Date Short Interest 1 B Most Recent Quarter 1 B
Share Holder Rights Risk 6 Regular Market Previous Close 11.42 Target Low Price 17.00
Gmt Off Set Milliseconds -18000000 Fifty Day Average 10.67 Open 11.44
Free Cashflow -70245504 State NC Dividend Yield 0.00 %
Return On Assets -0.4069 Time Zone Short Name EST Board Risk 9
Trailing Eps -1.62 Day Low 11.34 Address1 419 Davis Drive
Shares Outstanding 84 M Compensation Risk 10 Price Hint 2
Target High Price 31.00 Website https://www.liquidia.com 52 Week Change 0.6229
Average Volume 911667 Forward Eps -1.56 Recommendation Key strong_buy
Compensation As Of Epoch Date 1 B Quick Ratio 562.90 % Is_sp_500 False
Regular Market Day High 11.65 Profit Margins 0.00 % Debt To Equity 141.69
Fifty Two Week High 16.99 Day High 11.65 Shares Short 10 M
Regular Market Open 11.44 Industry Key biotechnology Earnings Growth 0.00 %
Enterprise To Revenue 52.03 Revenue Growth -23.50 % Shares Percent Shares Out 0.1225
Operating Cashflow -75070000 Currency USD Time Zone Full Name America/New_York
Market Cap 983 M Is_nasdaq_100 False Zip 27560
Quote Type EQUITY Industry Biotechnology Long Name Liquidia Corporation
Overall Risk 10 Regular Market Day Low 11.34 Held Percent Institutions 0.5431
Current Price 11.62 Address2 Suite 100 Enterprise To Ebitda -8.06
Financial Currency USD Current Ratio 6.08 Gross Margins 69.52 %
Industry Disp Biotechnology Number Of Analyst Opinions 9 Country United States
Float Shares 48 M Two Hundred Day Average 12.23 Governance Epoch Date 1 B
Enterprise Value 772 M Price To Sales Trailing12 Months 66.24 Forward PE -9.19
Regular Market Volume 485461 Ebitda -95836000 Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha 
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States.

Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).

The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion.

The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD.

Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.